Search

Displaying results 3441 - 3450 of 9333 in total
  1. Drug

    Thenalidine

    go.drugbank.com/drugs/DB04826
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to concerns involving neutropenia.

  2. Drug

    Fosaprepitant

    go.drugbank.com/drugs/DB06717
    ApprovedInvestigational

    It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.

  3. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

  4. Drug

    Levopropoxyphene

    go.drugbank.com/drugs/DB06793
    ApprovedWithdrawn

    Levopropoxyphene is a stereoisomer of propoxyphene in the form of 2S, 3R enantiomer. It was sold as an antitussive, but it was removed from the market in the 70s.

  5. Drug

    Nesiritide

    go.drugbank.com/drugs/DB04899
    ApprovedInvestigationalWithdrawn

    Nesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing).

  6. Drug

    Mevastatin

    go.drugbank.com/drugs/DB06693
    Experimental

    The compound was proposed to bind to the reductase enzyme and was named compactin. … It was the first discovered agent belonging to the class of cholesterol-lowering medications known as statins.

  7. Drug

    Obecabtagene autoleucel

    go.drugbank.com/drugs/DB17362
    ApprovedInvestigational

    [A265050] On November 8, 2024, obecabtagene autoleucel was approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia. … Obecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19.

    Categories: Genetically-modified Autologous T Cells, CD19-Directed Genetically Modified Autologous T-cell ImmunotherapiesSynonyms: SELF-INACTIVATING LENTIVIRAL VECTOR CONSISTING OF 5' FUSION BETWEEN THE CMV PROMOTER AND HIV LTR, WHERE THE CMV PROMOTER REPLACES THE U3 REGION., PACKAGING SIGNAL (.PSI.), THE REV RESPONSIVE ELEMENT (RRE) AND THE CENTRAL POLYPURINE TRACT (CPPT) ARE RETAIN
  8. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    It serves as a negative feedback mechanism in the coagulation cascade.

  9. Drug

    Zolasartan

    go.drugbank.com/drugs/DB20140
    Experimental

    The usage of the INN stem '-sartan' in the name indicates that Zolasartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

    Categories: Agents Acting on the Renin-Angiotensin System
  10. Drug

    Tildrakizumab

    go.drugbank.com/drugs/DB14004
    ApprovedInvestigational

    The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy … A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257].